Literature DB >> 25975970

A novel pathogenic variant in PRF1 associated with hemophagocytic lymphohistiocytosis.

Camilo Andrés Pérez Romero1, Isaura Pilar Sánchez, Sebastian Gutierrez-Hincapié, Jesús A Álvarez-Álvarez, Jaime Andres Pereañez, Rodrigo Ochoa, Carlos Enrique Muskus-López, Ruth G Eraso, Carolina Echeverry, Catalina Arango, José Luis Franco Restrepo, Claudia Milena Trujillo-Vargas.   

Abstract

Familial Hemophagocytic Lymphohistiocytosis type 2 (FHL2) results from mutations in PRF1. We described two unrelated individuals who presented with FHL, in whom severely impaired NK cytotoxicity and decrease perforin expression was observed. DNA sequencing of PRF1 demonstrated that both were not only heterozygous for the p.54R > C/91A > V haplotype but also presented with the novel variant p.47G > V at the perforin protein. Perforin mRNA was found to be increased in a individual with that genotype. A carrier of the novel variant also demonstrated altered perforin mRNA and protein expression. Phylogenetic analysis and multiple alignments with perforin orthologous demonstrated a high level of conservation at Gly47. PolyPhen-2 and PROVEAN predicted p.47G > V to be "probably damaging" and "deleterious", respectively. A thermodynamic analysis showed that this variant was highly stabilizing, decreasing the protein internal energy. The ab initio perforin molecular modeling indicated that Gly47 is buried inside the hydrophobic core of the MACPF domain, which is crucial for the lytic pore formation and protein oligomerization. After the in silico induction of the p.47G > V mutation, Val47 increased the interactions with the surrounding amino acids due to its size and physical properties, avoiding a proper conformational change of the domain. To our knowledge, this is the first description supporting that p.47G > V is a pathogenic variant that in conjunction with p.54R > C/91A > V might result in the clinical phenotype of FHL2.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25975970     DOI: 10.1007/s10875-015-0169-x

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  37 in total

1.  Adult onset and atypical presentation of hemophagocytic lymphohistiocytosis in siblings carrying PRF1 mutations.

Authors:  Rita Clementi; Lorenzo Emmi; Rita Maccario; Francesco Liotta; Lorenzo Moretta; Cesare Danesino; Maurizio Aricó
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

2.  HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

Authors:  Jan-Inge Henter; Annacarin Horne; Maurizio Aricó; R Maarten Egeler; Alexandra H Filipovich; Shinsaku Imashuku; Stephan Ladisch; Ken McClain; David Webb; Jacek Winiarski; Gritta Janka
Journal:  Pediatr Blood Cancer       Date:  2007-02       Impact factor: 3.167

3.  MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods.

Authors:  Koichiro Tamura; Daniel Peterson; Nicholas Peterson; Glen Stecher; Masatoshi Nei; Sudhir Kumar
Journal:  Mol Biol Evol       Date:  2011-05-04       Impact factor: 16.240

Review 4.  Familial and acquired hemophagocytic lymphohistiocytosis.

Authors:  G E Janka
Journal:  Annu Rev Med       Date:  2012       Impact factor: 13.739

5.  Analyses of the PRF1 gene in individuals with hemophagocytic lymphohystiocytosis reveal the common haplotype R54C/A91V in Colombian unrelated families associated with late onset disease.

Authors:  Isaura P Sánchez; Lucía C Leal-Esteban; Jesús A Álvarez-Álvarez; Camilo A Pérez-Romero; Julio C Orrego; Malyive L Serna; Yadira Coll; Yolanda Caicedo; Edwin Pardo-Díaz; Jacques Zimmer; Jack J Bleesing; José L Franco; Claudia M Trujillo-Vargas
Journal:  J Clin Immunol       Date:  2012-03-22       Impact factor: 8.317

6.  Localization and molecular modelling of the membrane-inserted domain of the ninth component of human complement and perforin.

Authors:  M C Peitsch; P Amiguet; R Guy; J Brunner; J V Maizel; J Tschopp
Journal:  Mol Immunol       Date:  1990-07       Impact factor: 4.407

7.  Fatal immune dysregulation due to a gain of glycosylation mutation in lymphocyte perforin.

Authors:  Jenny Chia; Kevin Thia; Amelia J Brennan; Margaret Little; Bronwyn Williams; Jamie A Lopez; Joseph A Trapani; Ilia Voskoboinik
Journal:  Blood       Date:  2011-12-20       Impact factor: 22.113

8.  Late-onset cases of familial hemophagocytic lymphohistiocytosis with missense perforin gene mutations.

Authors:  Ikuyo Ueda; Yumi Kurokawa; Kenichi Koike; Shuichi Ito; Akifumi Sakata; Tsutomu Matsumora; Takashi Fukushima; Akira Morimoto; Eiichi Ishii; Shinsaku Imashuku
Journal:  Am J Hematol       Date:  2007-06       Impact factor: 10.047

9.  NetCGlyc 1.0: prediction of mammalian C-mannosylation sites.

Authors:  Karin Julenius
Journal:  Glycobiology       Date:  2007-05-09       Impact factor: 4.313

10.  I-TASSER server for protein 3D structure prediction.

Authors:  Yang Zhang
Journal:  BMC Bioinformatics       Date:  2008-01-23       Impact factor: 3.169

View more
  4 in total

1.  RF1 Gene Mutation in Familial Hemophagocytic Lymphohistiocytosis 2: A Family Report and Literature Review.

Authors:  Yuan Shi; Zhidong Qiao; Xiaoduo Bi; Chenxin Zhang; Junxian Fu; Yuexin Jia; Guanglu Yang
Journal:  Pharmgenomics Pers Med       Date:  2021-12-16

Review 2.  Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma.

Authors:  Hikaru Nanamori; Yu Sawada
Journal:  Int J Mol Sci       Date:  2022-01-20       Impact factor: 5.923

3.  Effects of a natural nutritional supplement on immune cell infiltration and immune gene expression in exercise-induced injury.

Authors:  Feng Jiang; Rongfeng Yang; Diya Xue; Rong Li; Meiling Tan; Zhicong Zeng; Luhua Xu; Linling Liu; Yinzhi Song; Fengxia Lin
Journal:  Front Nutr       Date:  2022-09-16

4.  Late-onset hemophagocytic lymphohistiocytosis with neurological presentation.

Authors:  Sarah Benezech; Thierry Walzer; Emily Charrier; Damien Heidelberg; Geneviève De Saint-Basile; Yves Bertrand; Alexandre Belot
Journal:  Clin Case Rep       Date:  2017-09-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.